Pharma News

Malaria remains one of the greatest global health threats. In 2022, there were an estimated 247 million infections and over 600,000 deaths, mostly in sub-Saharan Africa. Innovative research approaches are therefore urgently needed to achieve long-term progress in prevention and treatment.

A new vaccine that boosts immunity against tuberculosis has been shown to be effective in pioneering pre-clinical trials, as part of a successful collaboration between three leading Australian research institutions. A study into the vaccine’s effectiveness, published in eBioMedicine, was led by experts from the Sydney Infectious Diseases Institute at University of Sydney, the Centenary Institute and the Monash Institute of Pharmaceutical Science at Monash University.

University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center scientists have discovered a novel subset of cancer-fighting immune cells that reside outside of their normal neighborhood, known as the tertiary lymphoid structure, where they become frustratingly dysfunctional when in close contact with tumors.

A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a new HIV therapy called lenacapavir in a population of patients in Uganda.

Galderma today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency and Swissmedic have granted the marketing authorization of nemolizumab for the treatment of both atopic dermatitis and prurigo nodularis in the UK and Switzerland, respectively. Specifically, the approvals are for nemolizumabs subcutaneous use for the treatment of moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors

Thousands of single changes in the nucleotides that make up the human genome have been associated with an increased risk of developing cancer. But until now, its not been clear which are directly responsible for the uncontrolled cellular growth that is the hallmark of the disease and which are simply coincidences or minor players.

MED-EL USA announced that the U.S. Food and Drug Administration approved the new SONNET 3 audio processor for MED-EL cochlear implants. SONNET 3 is the companys lightest and smallest behind-the-ear audio processor and features integrated wireless direct streaming capabilities.

The RNA inhibitor olpasiran significantly reduces a type of bad cholesterol thats associated with a high risk of cardiovascular events, according to results from an analysis by a Mount Sinai researcher of a phase 2 trial. The study reported that higher doses of olpasiran lowered the type of cholesterol called lipoprotein a by more than 95 percent in participants with atherosclerotic cardiovascular disease.